Apoptotic effect of thymoquinone on OVCAR3 cells via the P53 and CASP3 activation

Basit Öğe Kaydı
dc.authoridTuncer, Mehmet Cudi/0000-0001-7317-5467
dc.contributor.authorKaraosmanoglu, Ozge
dc.contributor.authorKamalak, Zeynep
dc.contributor.authorOzdemir, Ilhan
dc.contributor.authorTuncer, Mehmet Cudi
dc.contributor.authorOzturk, Tamil
dc.date.accessioned2025-01-27T20:17:10Z
dc.date.available2025-01-27T20:17:10Z
dc.date.issued2024
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractPurpose: The limitations in cancer treatment and the inadequacy of classical methods have made it necessary to discover therapeutics in cancer treatment. The cytotoxicity of thymoquinone, which has quite different properties in terms of biological activities, in ovarian cancer cells, and the changes in the expression levels of apoptotic genes (p53/caspase-3 (casp-3)) were investigated. Methods: In the study, thymoquinone (5, 50, 100, 250 and 500 mu M and 24, 48, 72 hours) were applied to ovarian adenocarcinoma cancer cell line (OVCAR3), at different concentrations. Cytotoxic effect of thymoquinone on OVCAR-3 cells were analyzed by MTT method, and apoptotic and pro-apoptotic gene expression levels (p53, Casp-3) of thymoquinone in cancer cells were analyzed by quantitative real-time polymerase chain reaction. Results: Thymoquinone, whose effect has been revealed in many types of cancer, was shown to significantly reduce the viability of OVCAR3 cancer cells depending on the dose and time (p < 0.05). It was also determined that Casp-3 and p53 gene expressions increased in OVCAR3 cells. Conclusion: Considering the in-vitro cytotoxic activity and apoptotic gene expressions of thymoquinone, an important treatment agent, since it is a promising agent for the future of cancer treatment, more comprehensive studies may pave the way for its clinical use.
dc.identifier.doi10.1590/acb399224
dc.identifier.issn0102-8650
dc.identifier.issn1678-2674
dc.identifier.pmid39536185
dc.identifier.scopus2-s2.0-85209391137
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1590/acb399224
dc.identifier.urihttps://hdl.handle.net/20.500.12428/21508
dc.identifier.volume39
dc.identifier.wosWOS:001356662900001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherActa Cirurgica Brasileira
dc.relation.ispartofActa Cirurgica Brasileira
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectCell Cycle. Apoptosis
dc.subjectAntineoplastic Agents
dc.subjectOvarian Neoplasms
dc.subjectCell Line
dc.titleApoptotic effect of thymoquinone on OVCAR3 cells via the P53 and CASP3 activation
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu